Navigation Links
Alkylating in Medical News

The Cancer Genome Atlas reports first results, Johns Hopkins Kimmel Cancer Center collaborates

... makes brain cancer cells more responsive to anticancer drugs known as alkylating agents. While brain cancer patients with the MGMT alteration respond better to the commonly-used alkylating agent temozolomide, the new TCGA research found that treatment also ...

Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

... tumor lysis syndrome, skin reactions, and other malignancies. TREANDA has a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

... Infusion II-35 Hematological Cancer Drug Classes II-35 Hypomethylating Agents & Antimetabolites II-35 Bisphosphonates II-36 alkylating Agents and DNA-Damaging Agents II-36 DNA-Repair Enzyme Inhibitors II-36 Histone Deacetylase Inhibitor II-36 Immunomodulators II-36 ...

Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009

... of 50. TRC102 is a small molecule inhibitor of base excision repair that improves the therapeutic index of commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an i.v. agent in ...

Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

... cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ...

Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

... cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ...

Vion Reports 2008 Second Quarter and Six-Month Results

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting

... developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common cancer therapies such as radiation and alkylating agents. ABT-888 completed a Phase 0 trial for patients with refractory solid tumors and lymphoid malignancies, and has entered several Phase I ...

Vion Pharmaceuticals to Appeal Nasdaq Delisting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...
Alkylating in Medical Technology

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

... on cancer stem cells. TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent ...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

... conjugate was well-tolerated in cynomolgous monkeys and mouse models. The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates (Abstract #1722) The effectiveness of a cleavable linker over a non-cleavable linker when used with ...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

... Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare ...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

... Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare ...

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma

... and apoptosis. In preclinical in vitro and animal model studies it shows activity against human tumors including melanoma and is synergistic with alkylating agents including dacarbazine. Fifty (50) patients were treated with Amplimexon at MTD (maximum tolerated dose) during the Phase II portion of the ...

More>>

Alkylating in Medical Dictionary

Acute myelogenous leukemia

... of myeloablative therapy with autologous bone marrow or peripheral blood stem cell support, as well as conventional chemotherapy -containing alkylating agents. The TdT stain differentiates between acute lymphoblastic leukemia (cells stain positive) and acute myelogenous leukemia (cells stain ...

Hemolytic

... anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[9] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia ). Auto immune hemolytic anemia without another underlying cause Drug -induced ...

Hemolytic anemia

... anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[9] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia ). Auto immune hemolytic anemia without another underlying cause Drug -induced ...

Hemorrhagic

... observation with treatment of infectious, hemorrhagic , or immunologic complications to a variety of therapeutic options, including steroids, alkylating agents, p urine analogs, ... Mesnex (mesna) tablets, 400 mg Indication: use as a prophylactic agent in reducing the incidence of ...

Immune hemolytic anemia

... anemia and/or thrombocytopenia can occur in patients with any stage of CLL.[9] Initial therapy involves corticosteroids with or without alkylating agents (fludarabine can worsen the hemolytic anemia ). Auto immune hemolytic anemia . Occurs when the body produces antibodies that coat red ...

Joints

... structure to the nose, ears, larynx , and other parts of the body. carzelesin An anti cancer drug that belongs to the family of drugs called alkylating agents. Pain in the bones or joints Swelling or discomfort in the abdomen (from an enlarged spleen ) Swollen lymph node s, especially in ...

Malignant melanoma

... is a cancer ; sometimes those are just normal changes in the nail color. Dacarbazine (da-KAR-ba-zeen) belongs to the group of medicines called alkylating agents. It is used to treat cancer of the lymph system and malignant melanoma (a type of skin cancer ). CONGENITAL GIANT PIGM ENT ED ...

Toxic

... by activating signaling pathways that regulate the cell cycle, DNA repair, and apo ptosis . Temodar (temozolomide) capsules An oral cyto toxic alkylating agent, one of a class of compounds known as imidazotetrazines. Indication: treatment of adult patients with refractory an aplastic astrocytoma, ...

More>>

Alkylating in Biological News

Researchers reveal structure of protein that repairs damage to cancer cells

... strategy to all kinds of other protein-DNA complexes. The AlkB and ABH2 proteins repair alkylation damage to DNA, including the damage caused by alkylating cancer treatments. Alkylation is the addition of certain chemical groups to DNA and is particularly harmful to rapidly growing cells such as ...
Alkylating in Biological Technology

Telik Reports Preclinical Results at AACR Annual Meeting

... of TLK58747; Abstract # 4515 Telik researchers identified a novel alkylating agent, TLK58747, which functions as a prodrug, without the need for ... an activation byproduct known to be associated with toxicity of other alkylating agents (acrolein). Key findings: TLK58747 inhibited ...

Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma

... treatment, never progress beyond the early stages of the disease. About Clearazide Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication. Nitrogen mustard has also demonstrated activity in other T-cell proliferating diseases such as ...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

... to 12:00 p.m. local time on Sunday, April 19, 2009. "The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates" (Abstract #1722), S. Gangwar - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April ...

Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)

... particularly attractive." About Onrigin Onrigin (laromustine) Injection, formerly known as Cloretazine(R) (VNP40101M), is a novel alkylating agent. Onrigin has been evaluated in over 800 patients in 16 clinical trials to date, including a pivotal Phase II trial in patients sixty years of ...

Medarex Announces Allowance of Investigational New Drug Application for Company's First Antibody-Drug Conjugate, MDX-1203

... Medarex's proprietary ADC technology uses a cytotoxic agent that is a potent, synthetically manufactured prodrug (a DNA minor-groove binding alkylating agent) which is attached to an antibody using a stable peptide-based linker. Medarex believes that its ADC technology overcomes many of the key ...

Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting

... cancer therapeutics. Vion has two agents in clinical trials. Onrigin(TM) (laromustine), formerly known as Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Reports 2008 First Quarter Results

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Files Plan With Nasdaq

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Reports 2007 Fourth Quarter and Year-End Results

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. ...
Alkylating in Biological Dictionary

Alkylating agents

... a free radical, a carbanion or a carbene . alkylating agents are widely used in ... An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches ...
Other Contents
(Date:4/17/2014)... of chronic inflammation in non-cancerous prostate tissue may have ... than those with no inflammation, according to results of ... Hopkins Kimmel Cancer Center. , The link between persistent ... so-called high-grade prostate cancer those with a Gleason ... of the most aggressive and rapidly growing prostate cancers. ...
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
(Date:4/17/2014)... modeling study suggests that fish consumption advisories for ... to long-lived contaminants like persistent organic pollutants (POPs). ... of researchers including University of Toronto Scarborough PhD ... at how different levels of environmental contamination, a ... chemicals in the body influenced exposure in her ...
(Date:4/17/2014)... in German . ... they also provide us with a continuous stream of information ... or sit still in a car the world glides ... retinas. Seemingly without effort, our brain calculates self-motion from this ... and a steady gaze during our own movements. Together with ...
(Date:4/17/2014)... professor Rajendra Singh Thursday as a "Champion of ... solar deployment in the residential, commercial and industrial ... of Electrical and Computer Engineering and director of ... local hero leading the charge across the country ... power and driving policy changes at the local ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
Other TagsOther Tags